Intellectual Disability
|
0.120 |
Biomarker
|
group |
HPO |
|
|
|
Amblyopia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Cryptorchidism
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Orbital separation excessive
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Microcephaly
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Nystagmus
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Open mouth (finding)
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Small testicle
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Global developmental delay
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Hypospadias
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
X- linked recessive
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Hyperopia, High
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Nystagmus, CTCAE 3.0
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Nystagmus, CTCAE 5.0
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
It is of great interest in the future to investigate the alteration of O-GlcNAc in different cancers since addition/removal of O-GlcNAc on oncoproteins, tumor suppressor proteins, and other tumor-related proteins very likely plays a key role in the pathogenesis of tumors.
|
14533811 |
2001 |
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
FSP06-specific CTL-clones killed peptide-sensitized target cells and tumor cell lines expressing both HLA-A0201 and mutant OGT proteins.
|
14601650 |
2003 |
Diabetes Mellitus, Experimental
|
0.200 |
Therapeutic
|
disease |
RGD |
Insulin stimulates and diabetes inhibits O-linked N-acetylglucosamine transferase and O-glycosylation of Sp1.
|
15561949 |
2004 |
Alzheimer's Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
More importantly, the decrease in O-GlcNAc correlated negatively with phosphorylation at most phosphorylation sites of tau protein, which is known to play a crucial role in the neurofibrillary degeneration of Alzheimer's disease.
|
19451179 |
2009 |
Alzheimer's Disease
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Reduced levels of O-GlcNAc have been observed in AD, suggesting a possible link to deficits in synaptic plasticity.
|
20563614 |
2011 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
Such studies have questioned a causal link between O-GlcNAc and Type 2 diabetes, but do offer potential for the study, and perhaps the treatment, of tauopathies.
|
20863281 |
2010 |
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Gene expression of O-GlcNAc cycling enzymes in human breast cancers.
|
21567137 |
2012 |
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
This result suggests that elevation in O-GlcNAc modification of proteins may be implicated in breast tumor progression and metastasis.
|
21567137 |
2012 |
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
This result suggests that elevation in O-GlcNAc modification of proteins may be implicated in breast tumor progression and metastasis.
|
21567137 |
2012 |
Cardiomegaly
|
0.200 |
Biomarker
|
phenotype |
RGD |
Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure.
|
22128088 |
2012 |
Heart failure
|
0.200 |
Biomarker
|
disease |
RGD |
Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure.
|
22128088 |
2012 |